Prothena | PRTA - Cost Of Sales

Stock Price
8.91
Daily Change
0.56 6.71%
Monthly
-2.41%
Yearly
-36.58%
Q1 Forecast
8.55

Prothena reported $28.94M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
ALKERMES USD 51.59M 2.13M Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Exelixis USD 18.57M 896K Sep/2025
Incyte USD 99M 20.23M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025